spl84
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 5, 2023 (NCT06217952)
Timeline
Indications
Studied for
Mechanism of action
- Cystic fibrosis transmembrane conductance regulatorANTISENSE INHIBITOR
CFTR antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06429176 | Phase 2 | Jul 1, 2024 | SpliSense Ltd. |
| NCT06217952 | Phase 1 | Feb 5, 2023 | SpliSense Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SpliSense Ltd. | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1